Certara (NASDAQ:CERT) Releases FY24 Earnings Guidance

Certara (NASDAQ:CERT) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $0.41-0.44 for the period, compared to the consensus earnings per share estimate of $0.41. The company issued revenue guidance of $380-385 million, compared to the consensus revenue estimate of $386.66 million. Certara also updated its FY 2024 guidance to 0.410-0.440 EPS.

Certara Stock Up 0.4 %

Shares of Certara stock traded up $0.04 during trading on Friday, reaching $11.03. The company’s stock had a trading volume of 1,081,810 shares, compared to its average volume of 786,430. The company has a 50-day simple moving average of $11.02 and a two-hundred day simple moving average of $13.70. Certara has a 1-year low of $9.99 and a 1-year high of $19.87. The company has a market cap of $1.77 billion, a price-to-earnings ratio of -22.06, a P/E/G ratio of 4.88 and a beta of 1.51. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.11 by $0.02. Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The business had revenue of $94.80 million during the quarter, compared to the consensus estimate of $95.51 million. During the same period in the previous year, the firm posted $0.06 earnings per share. The business’s revenue for the quarter was up 10.7% compared to the same quarter last year. As a group, equities analysts forecast that Certara will post 0.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a report on Friday, September 27th. Robert W. Baird dropped their price objective on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday. Finally, Barclays reduced their target price on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday. Six analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $15.92.

Insider Activity

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the transaction, the insider now owns 99,704 shares in the company, valued at approximately $1,125,658.16. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares of the company’s stock, valued at $1,125,658.16. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the sale, the insider now directly owns 50,091 shares of the company’s stock, valued at $552,503.73. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.39% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.